Madrigal Pharmaceuticals struck a global licensing agreement with Suzhou Ribo Life Science and Ribocure granting Madrigal rights to six preclinical siRNA programs targeting metabolic dysfunction‑associated steatohepatitis (MASH). The deal includes a $60 million upfront payment and up to $4.4 billion in development and commercial milestones, plus tiered royalties. Madrigal plans to pair the newly licensed siRNAs with its approved THR‑β agonist Rezdiffra, aiming to build a multi‑modality MASH portfolio. The company framed the transaction as part of a broader strategy to expand beyond a single product and to bring genetically targeted liver therapies into combination regimens. The transaction follows a series of deals Madrigal has struck to shore up differentiated pipeline assets for MASH and signals continued industry appetite — and large potential payouts — for liver‑directed RNA therapeutics.